"10.1371_journal.pmed.1001326","none","2012-10-16T00:00:00Z","Katherine E Tansey; Michel Guipponi; Nader Perroud; Guido Bondolfi; Enrico Domenici; David Evans; Stephanie K Hall; Joanna Hauser; Neven Henigsberg; Xiaolan Hu; Borut Jerman; Wolfgang Maier; Ole Mors; Michael O'Donovan; Tim J Peters; Anna Placentino; Marcella Rietschel; Daniel Souery; Katherine J Aitchison; Ian Craig; Anne Farmer; Jens R Wendland; Alain Malafosse; Peter Holmans; Glyn Lewis; Cathryn M Lewis; Tine Bryan StensbÃ¸l; Shitij Kapur; Peter McGuffin; Rudolf Uher","Institute of Psychiatry, Kings College London, London, United Kingdom; Department of Genetic Medicine and Laboratories, University Hospitals of Geneva, Geneva, Switzerland; Department of Psychiatry, University of Geneva, Geneva, Switzerland; Center of Excellence for Drug Discovery in Psychiatry, GlaxoSmithKline Medicines Research Centre, Verona, Italy; Pharma Research and Early Development, F. Hoffmannâ€La Roche, Basel, Switzerland; Medical Research Council CAiTE Centre, School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom; Molecular Medicine, Pfizer, Groton, Connecticut, United States of America; Laboratory of Psychiatric Genetics, Poznan University of Medical Sciences, Poznan, Poland; Croatian Institute for Brain Research, Medical School, University of Zagreb, Zagreb, Croatia; Department of Molecular and Biomedical Sciences, Jozef Stefan Institute, Ljubljana, Slovenia; Institute of Public Health of the Republic of Slovenia, Ljubljana, Slovenia; Department of Psychiatry, University of Bonn, Bonn, Germany; Centre for Psychiatric Research, Aarhus University Hospital, Risskov, Denmark; Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine and Neurology, School of Medicine, Cardiff University, Cardiff, United Kingdom; School of Clinical Sciences, University of Bristol, Bristol, United Kingdom; Psychiatric Unit 23, Department of Mental Health, Spedali Civili Hospital and Biological Psychiatry Unit, Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; Central Institute of Mental Health, Division of Genetic Epidemiology in Psychiatry, Mannheim, Germany; Department of Psychiatry, Erasme Academic Hospital, UniversitÃ© Libre de Bruxelles, Brussels, Belgium; Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada; School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom; Discovery Pharmacology Research, H. Lundbeck A/S, Copenhagen, Denmark; Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada","Conceived and designed the experiments: RU PM JRW TBS SK. Performed the experiments: MG. Analyzed the data: KET PH. Contributed reagents/materials/analysis tools: NP GB ED DE SKH JH NH XH BJ WM OM MOD TJP AP MR DS KJA IC AF AM GL PM. Wrote the first draft of the manuscript: KET RU. Contributed to the writing of the manuscript: KET MG NP GB ED DE SKH JH NH XH BJ WM OM MOD TJP AP MR DS KJA IC AF JRW AM PH GL CML TBS SK PM RU. ICMJE criteria for authorship read and met: KET MG NP GB ED DE SKH JH NH XH BJ WM OM MOD TJP AP MR DS KJA IC AF JRW AM PH GL CML TBS SK PM RU. Agree with manuscript results and conclusions: KET MG NP GB ED DE SKH JH NH XH BJ WM OM MOD TJP AP MR DS KJA IC AF JRW AM PH GL CML TBS SK PM RU. Supervised the statistical analyses: CML.","GB is a member of a national advisory board for Bristol-Myer Squibb and Pfizer and has received research funding from GlaxoSmithKline, Wyeth-Lederle, Bristol-Myers-Squibb, and Sanofi Aventis. ED and JRW are full-time employees of Roche. ED was a full time employee of GlaxoSmithKline when he undertook work on this study. SKH and XH are full-time employees of Pfizer. NH has participated in clinical trials sponsored by pharmaceutical companies including GlaxoSmithKline and Lundbeck and received honoraria for participating in expert panels from pharmaceutical companies including Lundbeck. MOâ€™Ds department received Â£2000 in lieu of an honorarium to MOD from Lilly as a result of his participation in sponsored symposia in 2012. Those symposia were unrelated to the contents of this manuscript. MOâ€™D holds grants from the Medical Research Council (UK), The Wellcome Trust, the National Institutes of Medicine (USA), and the European Union. None are relevant to the contents of this manuscript. DS is a member of a national advisory boards for Astra-Zeneca, Bristol-Myers Squibb, Eli Lilly, and Lundbeck. KJA is a member of a national advisory board for Johnson & Johnson, Lundbeck, Roche Diagnostics, and Bristol-Myers Squibb and Otsuka Pharmaceuticals Limited and has received consultancy fees and honoraria from Bristol-Myers Squibb, Lundbeck, Roche Molecular Systems, Roche Diagnostics, and Johnson & Johnson. KJA has received research and development consultancy fees and research support from Roche Diagnostics and Roche Molecular Systems. KJA has received research grants from Bristol-Myers Squibb and Otsuka Pharmaceuticals Limited; Johnson & Johnson Pharmaceutical Research and Development. PM and AF have previously received consultancy fees and honoraria for participating in expert panels from pharmaceutical companies including Lundbeck and GlaxoSmithKline, but have had no such income in the last 3 years. CML is on the Editorial Board of PLOS Medicine. TBS is a full time employee of Lundbeck. SK has received research funding from AstraZeneca, Bristol-Myers Squibb, and GlaxoSmithKline, and has served as consultant and/or speaker for AstraZeneca, Bioline, BMS-Otsuka, Eli Lilly, Janssen, Lundbeck, NeuroSearch, Pfizer, Roche, Servier, and Solvay Wyeth. All other authors have declared that no competing interests exist.","2012","10","Katherine E Tansey","KET",30,FALSE,5,1,2,2,TRUE,TRUE,FALSE,0,NA,FALSE
